ArticleEvidence-based complementary and alternative medicine : eCAM2022
Exosomal miR-221-3p Derived from Bone Marrow Mesenchymal Stem Cells Alleviates Asthma Progression by Targeting FGF2 and Inhibiting the ERK1/2 Signaling Pathway.
Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 11 citations in OpenAlex.
- Role of miR-191-3p in HDM-induced airway epithelial inflammation by targeting CD247 in allergic asthma.BMC immunology · 2026Article
- Extracellular-Vesicle-Associated Nucleic Acids in the Diagnosis and Treatment of Respiratory Diseases: A Narrative Review.Pharmaceutics · 2026Review
- The Immunomodulatory Role of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Asthma.International journal of nanomedicine · 2026Review
- Mesenchymal stem cell-derived exosomes: a new hope for improving asthma airway remodeling.Annals of medicine · 2025Review
- Extracellular Vesicles: Multimodal Tools for Diagnosis, Prognosis, and Therapy in Respiratory Diseases.Expert reviews in molecular medicine · 2025Review
- Therapeutic potential of hAMSCs in ligament regeneration: insights from the UCA1-miR-16-5p-FGF2 pathway.Stem cell research & therapy · 2025Article
- MicroRNA Signatures in Dental Pulp Stem Cells Following Nicotine Exposure.Dentistry journal · 2025Article
- The role of mesenchymal stem cell‑derived exosomes in asthma (Review).Molecular medicine reports · 2025Review
- Asthma and stem cell therapy.World journal of stem cells · 2025Review
- Article
- Roles of Exosomal miRNAs in Asthma: Mechanisms and Applications.Journal of asthma and allergy · 2024Review
- Exosomal miR-221-3p Derived from Bone Marrow Mesenchymal Stem Cells Alleviates Asthma Progression by Targeting FGF2 and Inhibiting the ERK1/2 Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Mesenchymal Stem/Stromal Cells in Asthma Therapy: Mechanisms and Strategies for Enhancement.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes derived from human bone marrow mesenchymal stem cells (BMSCs) play potential protective roles in asthma. However, the underlying mechanisms remain not fully elucidated. Herein, exosomes were isolated from BMSCs, and the morphology, particle size, and exosome marker proteins were identified by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot, respectively. Then airway smooth muscle cells (ASMCs) were treated with transforming growth factor-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.